An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients with at least 65 years of age with essential hypertension, using 24-hour ABPM [ambulatory BP monitoring], with lisinopril 10 mg as a reference.

Trial Profile

An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients with at least 65 years of age with essential hypertension, using 24-hour ABPM [ambulatory BP monitoring], with lisinopril 10 mg as a reference.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2016

At a glance

  • Drugs Aliskiren (Primary) ; Lisinopril
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top